Brain-derived neurotrophic factor (BDNF) is known to be related to normal neuronal function and energy homeostasis, and increased levels of serum BDNF are associated with improved cognitive function, including learning and memory. The present invention relates generally to a method of preparing compositions for increasing the serum levels of brain-derived neurotrophic factor (BDNF). In particular, the method relates to combining a curcuminoid or a derivative thereof with a dispersing agent under high shear, and administering the composition to a subject in need thereof to increase the serum levels of Brain-derived neurotrophic factor (BDNF) to improve cognitive function, wherein the composition may be co-administered with iron.

Brain-derived neurotrophic factor (BDNF) is known to be related to normal neuronal function and energy homeostasis, and increased levels of serum BDNF are associated with improved cognitive function, including learning and memory. The present invention relates generally to a method of preparing compositions for increasing the serum levels of brain-derived neurotrophic factor (BDNF). In particular, the method relates to combining a curcuminoid or a derivative thereof with a dispersing agent under high shear, and administering the composition to a subject in need thereof to increase the serum levels of Brain-derived neurotrophic factor (BDNF) to improve cognitive function, wherein the composition may be co-administered with iron.

Methods and formulations for treating and preventing LONG COVID sequelae are provided. An example method treats loss of smell and taste from SARS-CoV-2 infection, including assessing the patient, administering a composition with dosage between 1750-3600 mg per day, wherein the composition comprises a mixture of at least a withanolide-A, a boswellic acid, a [6]-gingerol, and a curcuminoid. Another example method treats memory loss or brain fog from SARS-CoV-2 infection, including assessing the patient, and administering a regenerative and neuroprotective composition comprising a mixture of withanoside VI, withanolide A, a Boswellia serrata plant, a Zingiber officinale rhizome, and a Curcuma longa rhizome. The compositions were found effective, achieving statistical significance in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial.

Methods and formulations for treating and preventing LONG COVID sequelae are provided. An example method treats loss of smell and taste from SARS-CoV-2 infection, including assessing the patient, administering a composition with dosage between 1750-3600 mg per day, wherein the composition comprises a mixture of at least a withanolide-A, a boswellic acid, a [6]-gingerol, and a curcuminoid. Another example method treats memory loss or brain fog from SARS-CoV-2 infection, including assessing the patient, and administering a regenerative and neuroprotective composition comprising a mixture of withanoside VI, withanolide A, a Boswellia serrata plant, a Zingiber officinale rhizome, and a Curcuma longa rhizome. The compositions were found effective, achieving statistical significance in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial.

Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

A stable liquid formulation is provided. The liquid formulation includes a composition of active ingredients paeonol and apocynin. Methods of production of such a formation and treatment of diseases administering such a formulation are also provided.

A stable liquid formulation is provided. The liquid formulation includes a composition of active ingredients paeonol and apocynin. Methods of production of such a formation and treatment of diseases administering such a formulation are also provided.

A stable liquid formulation is provided. The liquid formulation includes a composition of active ingredients paeonol and apocynin. Methods of production of such a formation and treatment of diseases administering such a formulation are also provided.

Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.

Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.